UK Diabetes Drugs Market Analysis Report [2022-30]

UK Diabetes Drugs Market Analysis

$ 3999

The UK diabetes drugs market size was valued at $1.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $2.21 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The UK diabetes drug market will grow because UK has a strong pharmaceutical industry with several established companies and emerging biotech companies developing new diabetes drugs. The key market players are AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Novo Nordisk, Sanofi, and others.

ID: IN10GBPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Chandani Patel

Buy Now

UK Diabetes Drugs Market Executive Summary

The UK diabetes drugs market size was valued at $1.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $2.21 Bn in 2030. According to the World Bank, the United Kingdom had a Gross Domestic Product (GDP) of $2.63 trillion in 2020. In terms of health expenditure, the UK spent 9.8% of its GDP on healthcare in 2019, according to data from the Organisation for Economic Co-operation and Development (OECD). Compared to other high-income countries, the UK's health expenditure as a share of GDP is slightly below the OECD average of 10.3%. However, the UK has a publicly funded National Health Service (NHS) that provides free or low-cost healthcare to all UK residents, which makes the UK's healthcare system unique among high-income countries.

Diabetes is a significant health issue in the UK, affecting an estimated 3.9 Mn people, or about 6% of the population. The prevalence of diabetes in the UK is expected to continue to increase due to factors such as an aging population, changing lifestyles, and rising obesity rates. The increasing prevalence of diabetes in the UK has a significant impact on the diabetes drugs market. With more people being diagnosed with diabetes, there is a growing demand for diabetes drugs to help manage the disease. This has led to a growing market for diabetes drugs in the UK, with both established pharmaceutical companies and emerging biotech companies developing new treatments to address this demand.

At the same time, the UK government's cost-containment measures, including the use of cost-effectiveness assessments by NICE, have also had an impact on the diabetes drugs market. While these measures have helped to ensure that the NHS provides cost-effective treatments, they have also limited the availability of some newer, more expensive diabetes drugs, which may be less cost-effective in the short term but may offer significant benefits in the long term.

Overall, the diabetes drugs market in the UK is driven by both the growing demand for diabetes treatments and the need to balance cost-effectiveness with the need for innovation and patient access to new and effective therapies. As the prevalence of diabetes in the UK continues to increase, it is likely that the demand for diabetes drugs will also continue to grow new opportunities in the market.

uk diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Increasing prevalence of diabetes: Diabetes is a significant health issue in the UK, affecting an estimated 3.9 Mn people. With the prevalence of diabetes expected to continue to rise, there is a growing demand for diabetes drugs to manage the disease.

A growing pipeline of innovative drugs: The UK has a strong pharmaceutical industry with several established companies and emerging biotech companies developing new diabetes drugs. The increasing pipeline of innovative drugs provides opportunities for growth in the diabetes drugs market.

Government support: The UK government has demonstrated a commitment to investing in healthcare and promoting the use of innovative treatments. This support can create a favorable environment for pharmaceutical companies to develop and market new diabetes drugs.

Market Restraints

Cost-containment measures: The UK government has implemented cost-containment measures to manage healthcare spending, including the use of cost-effectiveness assessments by NICE. These measures can limit the availability of some newer, more expensive diabetes drugs, which may be less cost-effective in the short term.

Patent expirations: Several key diabetes drugs have lost or are expected to lose patent protection, which can lead to increased competition from generic versions of these drugs.

Stringent regulations: The UK has stringent regulations governing the approval of new drugs, which can create barriers to entry for smaller pharmaceutical companies and slow the development of new treatments.

Competitive Landscape

Key Players

AstraZeneca
GlaxoSmithKline
Eli Lilly and Company
Novo Nordisk
Sanofi
Johnson & Johnson
Abott
Bayer Pharmaceuticals
Merck
Boehringer Ingelheim
Novartis

Notable deals

January 2021, AstraZeneca and Provention Bio announced a collaboration to develop and commercialize a new type 1 diabetes drug called PRV-015. Under the terms of the deal, AstraZeneca made an initial payment of $100 Mn to Provention Bio, with additional milestone payments possible in the future.

April 2021, Eli Lilly and Company and Zealand Pharma announced a collaboration to develop and commercialize a new once-weekly GLP-1 analogue for the treatment of type 2 diabetes. Under the terms of the deal, Eli Lilly and Company made an upfront payment of $40 Mn to Zealand Pharma, with additional milestone payments possible in the future.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In the UK, diabetes drugs are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA), which is responsible for ensuring the safety, efficacy, and quality of drugs in the UK. The regulatory process for diabetes drugs in the UK involves several stages, including pre-clinical studies, clinical trials, and post-marketing surveillance. The MHRA reviews drug applications and conducts inspections of manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP).

In terms of reimbursement, diabetes drugs in the UK are covered by the National Health Service (NHS), which provides free or low-cost healthcare to UK residents. Under the NHS, patients are responsible for paying a prescription fee for each medication they receive, unless they are exempt due to certain medical conditions or income levels. The cost of prescription fees is set by the government and may change from year to year.

The NHS also has a system for evaluating the cost-effectiveness of prescription drugs, known as the National Institute for Health and Care Excellence (NICE). NICE conducts assessments of new drugs and makes recommendations to the NHS on whether or not they should be funded. These assessments take into account the clinical effectiveness of the drug as well as its cost-effectiveness compared to other treatments. NICE recommendations are not binding, but they are influential in NHS funding decisions.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.